Logo Image
Opinion|Videos|September 3, 2025

Highlighting Deuruxolitinib for Alopecia Areata

Key Takeaways

  • Alopecia areata is a chronic autoimmune disorder causing non-scarring hair loss due to immune system attacks on hair follicles.
  • Breakdown of immune privilege in hair follicles leads to infiltration by cytotoxic T cells, particularly CD8+ T cells.
SHOW MORE

Panelists discuss how deuruxolitinib, evaluated in the THRIVE-AA1 and THRIVE-AA2 phase 3 trials, differs from previous Janus kinase (JAK) inhibitors in its formulation and efficacy, and why ensuring long-term patient adherence through 24 weeks is crucial for treatment durability and success.

Episodes in this series

Video content above is prompted by the following:

  1. Mostaghimi: Deuruxolitinib has been evaluated in the THRIVE-AA1 and THRIVE-AA2 multinational phase 3 clinical trials gaining FDA approval in 2024. How did this JAK inhibitor differ from the last past two 2 JAK inhibitors approved in the previous 2 years?
    1. Durability is often an issue seen in studies where patients don’t remain on therapies long-term. Why is it so important to see the majority of patients staying on deuruxolitinib through 24 weeks?
    2. How does the durability of the different JAK inhibitors compare?

Related Content